CYPHERPUNK TECHNOLOGIES INC. current report, 10 April 2024

Full document

Business Context and Reporting Period

Company: Leap Therapeutics, Inc. (Note: Request metadata listed "Cypherpunk Technologies Inc." but the filing text identifies the registrant as Leap Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2024
Reporting Period: Event-based report regarding a material definitive agreement entered into on April 10, 2024.

Key Financial Metrics and Transaction Details

This filing reports a private placement transaction rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:

  • Aggregate Gross Proceeds: Approximately $40 million.
  • Common Stock Issued: 12,660,993 shares at $2.82 per share.
  • Pre-Funded Warrants Issued: Warrants to purchase 1,523,404 shares at $2.819 per warrant.
  • Expected Closing Date: April 15, 2024.
  • Debt and Liquidity: The filing does not provide current debt levels or liquidity ratios; proceeds are intended to fund operations and working capital.

Material Changes and Use of Proceeds

The primary material change is the entry into a Securities Purchase Agreement with institutional investors. The Company intends to use net proceeds for the following specific purposes:

  • Expanding the randomized controlled Part B of the DeFianCe Study (second-line colorectal cancer) from 130 to 180 patients.
  • Enabling data maturation in the randomized controlled Part C of the DisTinGuish study (first-line gastric cancer).
  • Manufacturing clinical trial material to permit Phase 3 readiness.
  • Working capital and general corporate purposes.

Guidance, Risks, and Unusual Items

Transaction Terms:

  • Exercise Restrictions: Pre-Funded Warrants contain a "blocker" provision limiting beneficial ownership to 4.99% (increasable to 19.99% with 61 days' notice).
  • Registration Rights: The Company must file a Form S-3 registration statement within 30 days of closing and use commercially reasonable efforts to have it declared effective within 90 days (or 120 days if reviewed by the SEC).
  • Penalties: Customary cash penalties apply if the Company fails to meet specified filing and effectiveness time periods.
Risks and Forward-Looking Statements:
  • The filing contains forward-looking statements regarding expected proceeds, use of proceeds, closing timing, and warrant exercise.
  • Actual results may differ materially due to risks detailed in the Company's Form 10-K and 10-Q filings.
  • The transaction is subject to customary closing conditions.
Unusual Items:
  • The filing includes a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) posted on April 11, 2024.

Investor Verification Checklist

  • Verify the actual closing of the transaction on or around April 15, 2024.
  • Confirm the filing of the Form S-3 registration statement within 30 days of closing.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
  • Monitor the Company's periodic reports (10-K/10-Q) for updated cash position and burn rate post-transaction.
  • Check for any updates on the DeFianCe and DisTinGuish study timelines and patient enrollment numbers.